Asset Details
Do you wish to reserve the book?
Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)
Do you wish to request the book?
Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Clinical diagnostic value of targeted next‑generation sequencing for infectious diseases (Review)
2024
Overview
As sequencing technology transitions from research to clinical settings, due to technological maturity and cost reductions, metagenomic next-generation sequencing (mNGS) is increasingly used. This shift underscores the growing need for more cost-effective and universally accessible sequencing assays to improve patient care and public health. Therefore, targeted NGS (tNGS) is gaining prominence. tNGS involves enrichment of target pathogens in patient samples based on multiplex PCR amplification or probe capture with excellent sensitivity. It is increasingly used in clinical diagnostics due to its practicality and efficiency. The present review compares the principles of different enrichment methods. The high positivity rate of tNGS in the detection of pathogens was found in respiratory samples with specific instances. tNGS maintains high sensitivity (70.8-95.0%) in samples with low pathogen loads, including blood and cerebrospinal fluid. Furthermore, tNGS is effective in detecting drug-resistant strains of Mycobacterium tuberculosis, allowing identification of resistance genes and guiding clinical treatment decisions, which is difficult to achieve with mNGS. In the present review, the application of tNGS in clinical settings and its current limitations are assessed. The continued development of tNGS has the potential to refine diagnostic accuracy and treatment efficacy and improving infectious disease management. However, further research to overcome technical challenges such as workflow time and cost is required.
Publisher
D.A. Spandidos,Spandidos Publications,Spandidos Publications UK Ltd
Subject
/ Antigens
/ Communicable Diseases - diagnosis
/ Communicable Diseases - genetics
/ Communicable Diseases - microbiology
/ COVID-19
/ CRISPR
/ Design
/ Diagnostic equipment (Medical)
/ Genes
/ Genomes
/ High-Throughput Nucleotide Sequencing - methods
/ Humans
/ metagenomic next-generation sequencing
/ Methods
/ Molecular Diagnostic Techniques - methods
/ Mutation
/ Patients
/ primer amplification enrichment
/ Severe acute respiratory syndrome coronavirus 2
/ targeted next-generation sequencing
/ Viruses
